CCA
PTCT icon

Catalyst Capital Advisors’s PTC Therapeutics PTCT Stock Holding History

Catalyst Capital Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-30,666
Closed -$658K – 304
2013
Q3 		$658K Buy
+30,666
New +$533K 0.36% 119

Other funds holding PTCT

BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Catalyst Capital Advisors's PTCT Position: Q4 2013 in Review

Catalyst Capital Advisors sold out of PTC Therapeutics (PTCT) in Q4 2013, closing a stake of 30,666 shares — an estimated $658K sold.

Catalyst Capital Advisors first reported a position in PTCT in Q3 2013 and held it in 1 quarter. The position peaked at $658K in Q3 2013. 61 funds tracked by Wall St. Rank hold PTCT as of Q4 2013.

  • Catalyst Capital Advisors reported no remaining PTC Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Catalyst Capital Advisors sold 30,666 PTC Therapeutics shares in Q4 2013, an estimated $658K.
  • Catalyst Capital Advisors first reported a position in PTC Therapeutics in Q3 2013 and held it in 1 quarter.
  • Catalyst Capital Advisors's PTC Therapeutics position peaked at $658K in Q3 2013.
  • 61 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2013.

Based on Catalyst Capital Advisors's 13F filing for Q4 2013, filed 13 Feb 2014.